Nomura Asset Management Co. Ltd. Grows Holdings in Pfizer Inc. (NYSE:PFE)

Nomura Asset Management Co. Ltd. raised its position in shares of Pfizer Inc. (NYSE:PFE) by 5.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,749,702 shares of the biopharmaceutical company’s stock after purchasing an additional 92,596 shares during the quarter. Nomura Asset Management Co. Ltd.’s holdings in Pfizer were worth $50,636,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of PFE. M&G Plc grew its position in shares of Pfizer by 14.5% during the second quarter. M&G Plc now owns 813,423 shares of the biopharmaceutical company’s stock worth $22,776,000 after purchasing an additional 103,254 shares in the last quarter. Maia Wealth LLC bought a new stake in shares of Pfizer during the second quarter valued at approximately $372,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Pfizer by 1.4% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 1,648,811 shares of the biopharmaceutical company’s stock worth $46,134,000 after buying an additional 21,970 shares in the last quarter. Great Valley Advisor Group Inc. boosted its position in shares of Pfizer by 6.1% during the second quarter. Great Valley Advisor Group Inc. now owns 192,028 shares of the biopharmaceutical company’s stock worth $5,373,000 after acquiring an additional 10,993 shares during the last quarter. Finally, ORG Partners LLC grew its stake in Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 44,458 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. Evercore ISI raised shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wolfe Research assumed coverage on Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 price target for the company. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Citigroup began coverage on shares of Pfizer in a report on Friday, October 25th. They issued a “neutral” rating and a $30.00 target price for the company. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.92.

Insiders Place Their Bets

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction dated Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Stock Up 1.5 %

Shares of NYSE PFE opened at $26.12 on Tuesday. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The firm has a market capitalization of $148.02 billion, a price-to-earnings ratio of 35.30, a PEG ratio of 0.70 and a beta of 0.65. The stock has a 50 day moving average price of $27.42 and a 200 day moving average price of $28.36. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) earnings per share. Sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 2nd. Investors of record on Friday, November 8th were paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 6.43%. The ex-dividend date of this dividend was Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.